- Home
- ARDT vs SDGR Comparison
ARDT vs SDGR Comparison
Compare ARDT & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDT
- SDGR
- Stock Information
- Founded
- ARDT 2001
- SDGR 1990
- Country
- ARDT United States
- SDGR United States
- Employees
- ARDT N/A
- SDGR N/A
- Industry
- ARDT
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- ARDT
- SDGR Health Care
- Exchange
- ARDT NYSE
- SDGR Nasdaq
- Market Cap
- ARDT 2.1B
- SDGR 1.7B
- IPO Year
- ARDT 2024
- SDGR 2020
- Fundamental
- Price
- ARDT $13.04
- SDGR $20.46
- Analyst Decision
- ARDT Buy
- SDGR Buy
- Analyst Count
- ARDT 13
- SDGR 5
- Target Price
- ARDT $20.77
- SDGR $32.80
- AVG Volume (30 Days)
- ARDT 252.5K
- SDGR 1.2M
- Earning Date
- ARDT 08-13-2025
- SDGR 07-30-2025
- Dividend Yield
- ARDT N/A
- SDGR N/A
- EPS Growth
- ARDT 935.52
- SDGR N/A
- EPS
- ARDT 1.64
- SDGR N/A
- Revenue
- ARDT $6,024,260,000.00
- SDGR $230,492,000.00
- Revenue This Year
- ARDT $8.25
- SDGR $24.44
- Revenue Next Year
- ARDT $5.56
- SDGR $22.17
- P/E Ratio
- ARDT $7.89
- SDGR N/A
- Revenue Growth
- ARDT 8.91
- SDGR 22.29
- 52 Week Low
- ARDT $11.31
- SDGR $16.60
- 52 Week High
- ARDT $20.72
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- ARDT N/A
- SDGR 37.57
- Support Level
- ARDT N/A
- SDGR $20.90
- Resistance Level
- ARDT N/A
- SDGR $21.62
- Average True Range (ATR)
- ARDT 0.00
- SDGR 1.37
- MACD
- ARDT 0.00
- SDGR -0.35
- Stochastic Oscillator
- ARDT 0.00
- SDGR 4.46
About ARDT ARDENT HEALTH PARTNERS INC
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in services and technologies, Ardent is passionate about making healthcare easier to access.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.